Immunic, Inc. announced the publication of preclinical data confirming that vidofludimus calcium acts as a potent nuclear receptor related 1 activator, in addition to its known mode of action as a dihydroorotate dehydrogenase inhibitor.
Immunic, Inc. announced the publication of preclinical data confirming that vidofludimus calcium acts as a potent nuclear receptor related 1 activator, in addition to its known mode of action as a dihydroorotate dehydrogenase inhibitor.